The Movement Disorder Society,
U.S. Department of Defense, the
National Institutes of Health, and
professional associations and
patient voluntary organizations.
World Parkinson Congress Inc.
710 West 168th Street, 3rd Floor
New York, NY 10032 USA
info@worldpdcongress.org
Copyright © 2006
Satellite Sessions
PDD/DLB at the Crossroads - an Approved Satellite Symposium:
The purpose of the symposium is to examine thoroughly the basic and clinical aspects of the dementias associated with Parkinson's disease (PDD) and the entity that has become known as Dementia with Lewy Bodies (DLB). The discovery of alpha-synuclein in 1997 has brought PDD and DLB close together on the same clinico-pathologic spectrum of neurodegeneration, and it is the extent of this connectivity that the invited experts will address in two days of lecture and interactive discussion. The speakers will define areas of agreement and controversy with the goal of reaching a unifying consensus on pathobiology and the boundaries of clinical diagnosis of the two disorders. People attending the symposium, including patients and caregivers, will have the opportunity to participate in breakout discussion groups. The closing group session at the end of day two will bring all points of view together for a spirited attempt to bridge any gaps and to define those areas that need further debate and research. This satellite symposium will be held on Tuesday, February 21 from 8:00 a.m. to 5:30 p.m. and on Wednesday, February 22 from 8:00 a.m. to 3:00 p.m. at the Washington Convention Center. For more information or to register, please contact Dawn McHale at dawn.mchale@med.va.gov or call 1 (215) 823-5800 x2238.
For more information please visit www.pdd-dlbcrossroads.com
This program is supported by grants from the following organizations and corporations:
- Forest Laboratories, Inc.
- Lehigh Valley Parkinson's Disease Support Group
- The Movement Disorder Society
- National Parkinson Foundation, Inc.
- National Institute of Neurological Diseases and Stroke
- Novartis Pharmaceuticals Corporations
- Parkinson's Disease Foundation, Inc.
- Schwarz Pharma, Inc.